Quality of Life and Pain Relief during Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma

Tomasz (Tom) Beer, Kristine M. Eilers, Mark Garzotto, Yi Ching Hsieh, Motomi (Tomi) Mori

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

BACKGROUND. The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma. METHODS. Analgesic response was defined as a 2-point reduction on the Present Pain Intensity (PPI) scale (or compete relief if baseline PPI was 1) without an increase in analgesic use or a 50% decrease in analgesic medication use without an increase in pain, maintained for ≥4 weeks. Pain, pain medication consumption, and QOL (measured by the European Organization for Research and Treatment of Cancer QLQ-C30) were evaluated every 4 weeks. RESULTS. Treatment resulted in an analgesic response in 14 of 29 evaluable patients (48%; 95% confidence interval [95% CI], 30-67%). The median time to symptomatic progression in the 14 patients who met criteria for analgesic response was 41 weeks (95% CI, 26-56 weeks). Worsening in physical and role functioning, fatigue, appetite, and global health status and improvement in constipation were detected using the QLQ-C30 QOL questionnaire. CONCLUSIONS. Significant analgesic activity was demonstrated, although worsening in several QOL domains was observed in a patient population with relatively low pain intensity (median PPI, 2).

Original languageEnglish (US)
Pages (from-to)758-763
Number of pages6
JournalCancer
Volume100
Issue number4
DOIs
StatePublished - Feb 15 2004

Fingerprint

docetaxel
Calcitriol
Androgens
Analgesics
Prostate
Quality of Life
Carcinoma
Pain
Therapeutics
Confidence Intervals
Appetite
Constipation
Health Status
Fatigue

Keywords

  • Calcitriol
  • Docetaxel
  • Prostate carcinoma
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quality of Life and Pain Relief during Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma. / Beer, Tomasz (Tom); Eilers, Kristine M.; Garzotto, Mark; Hsieh, Yi Ching; Mori, Motomi (Tomi).

In: Cancer, Vol. 100, No. 4, 15.02.2004, p. 758-763.

Research output: Contribution to journalArticle

@article{cc6b323713e24464aa30d85013998c88,
title = "Quality of Life and Pain Relief during Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma",
abstract = "BACKGROUND. The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma. METHODS. Analgesic response was defined as a 2-point reduction on the Present Pain Intensity (PPI) scale (or compete relief if baseline PPI was 1) without an increase in analgesic use or a 50{\%} decrease in analgesic medication use without an increase in pain, maintained for ≥4 weeks. Pain, pain medication consumption, and QOL (measured by the European Organization for Research and Treatment of Cancer QLQ-C30) were evaluated every 4 weeks. RESULTS. Treatment resulted in an analgesic response in 14 of 29 evaluable patients (48{\%}; 95{\%} confidence interval [95{\%} CI], 30-67{\%}). The median time to symptomatic progression in the 14 patients who met criteria for analgesic response was 41 weeks (95{\%} CI, 26-56 weeks). Worsening in physical and role functioning, fatigue, appetite, and global health status and improvement in constipation were detected using the QLQ-C30 QOL questionnaire. CONCLUSIONS. Significant analgesic activity was demonstrated, although worsening in several QOL domains was observed in a patient population with relatively low pain intensity (median PPI, 2).",
keywords = "Calcitriol, Docetaxel, Prostate carcinoma, Quality of life",
author = "Beer, {Tomasz (Tom)} and Eilers, {Kristine M.} and Mark Garzotto and Hsieh, {Yi Ching} and Mori, {Motomi (Tomi)}",
year = "2004",
month = "2",
day = "15",
doi = "10.1002/cncr.20024",
language = "English (US)",
volume = "100",
pages = "758--763",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Quality of Life and Pain Relief during Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma

AU - Beer, Tomasz (Tom)

AU - Eilers, Kristine M.

AU - Garzotto, Mark

AU - Hsieh, Yi Ching

AU - Mori, Motomi (Tomi)

PY - 2004/2/15

Y1 - 2004/2/15

N2 - BACKGROUND. The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma. METHODS. Analgesic response was defined as a 2-point reduction on the Present Pain Intensity (PPI) scale (or compete relief if baseline PPI was 1) without an increase in analgesic use or a 50% decrease in analgesic medication use without an increase in pain, maintained for ≥4 weeks. Pain, pain medication consumption, and QOL (measured by the European Organization for Research and Treatment of Cancer QLQ-C30) were evaluated every 4 weeks. RESULTS. Treatment resulted in an analgesic response in 14 of 29 evaluable patients (48%; 95% confidence interval [95% CI], 30-67%). The median time to symptomatic progression in the 14 patients who met criteria for analgesic response was 41 weeks (95% CI, 26-56 weeks). Worsening in physical and role functioning, fatigue, appetite, and global health status and improvement in constipation were detected using the QLQ-C30 QOL questionnaire. CONCLUSIONS. Significant analgesic activity was demonstrated, although worsening in several QOL domains was observed in a patient population with relatively low pain intensity (median PPI, 2).

AB - BACKGROUND. The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma. METHODS. Analgesic response was defined as a 2-point reduction on the Present Pain Intensity (PPI) scale (or compete relief if baseline PPI was 1) without an increase in analgesic use or a 50% decrease in analgesic medication use without an increase in pain, maintained for ≥4 weeks. Pain, pain medication consumption, and QOL (measured by the European Organization for Research and Treatment of Cancer QLQ-C30) were evaluated every 4 weeks. RESULTS. Treatment resulted in an analgesic response in 14 of 29 evaluable patients (48%; 95% confidence interval [95% CI], 30-67%). The median time to symptomatic progression in the 14 patients who met criteria for analgesic response was 41 weeks (95% CI, 26-56 weeks). Worsening in physical and role functioning, fatigue, appetite, and global health status and improvement in constipation were detected using the QLQ-C30 QOL questionnaire. CONCLUSIONS. Significant analgesic activity was demonstrated, although worsening in several QOL domains was observed in a patient population with relatively low pain intensity (median PPI, 2).

KW - Calcitriol

KW - Docetaxel

KW - Prostate carcinoma

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0842325864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842325864&partnerID=8YFLogxK

U2 - 10.1002/cncr.20024

DO - 10.1002/cncr.20024

M3 - Article

C2 - 14770432

AN - SCOPUS:0842325864

VL - 100

SP - 758

EP - 763

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -